Commercialising European innovation in China
Dynasty Biotechnology funds UK and European life sciences innovation by a novel method: we acquire or license IP from an innovative company (the ‘technology Sponsor’) in return for upfront fees and a share of downstream value – known as royalty-based financing. We also work with the Sino-UK Fund, bringing Chinese capital to Europe for direct investment, and providing access to the Chinese market for investee companies. (See Sino-UK Fund VIDEO: “Chinese capital is coming …” by PharmaVentures) The application of Chinese funding to support the development of European innovation represents a new source of funding for growing biotech, cleantech and agritech businesses.
Dynasty mobilises a partnership of excellence by applying the best skills of both Europe and China:
The power of UK innovation:
The UK is Europe’s top R&D location and the world’s second largest research base after the US. Funding for UK science has doubled in the last 10 years and the UK is now home to the two largest pharma companies – AZ and GSK. Importantly around 20% of the world’s marketed medicines today originate from UK innovation.
The power of Chinese development:
China provides the development and manufacturing skills. China also represents one of the most important and growing global markets for Western medicines, with a large population and rising incidence of ‘Western’ diseases. There is growing demand for the Dynasty medicines.
Our access and project pipeline is not limited to the UK: The Dynasty team is well connected across Europe and has access to all major pharma companies, science parks and investors. We are able to select Phase I and Phase II projects that satisfy healthcare needs in China and we hand-pick each project or technology on the basis of the quality of the science, viability for development and suitability for the Chinese market.
Dynasty has the support of the UK Government, complementing the UK Government’s own renewed commitment to Sino-UK trade. Dynasty also supports the powerful French, German and Swiss initiatives and we seek to encourage and support all Sino-European life-sciences innovation.
Click here for UK access for Chinese pharma companies or here for Contact Us